Historique
Bulletin de Périodique
Addiction , Vol.107, Suppl.1 - November 2012 - Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study
Auteur(s) :
BANDSTRA, E. S. (Éditeur scientifique)
Paru le :
15/11/2012
Année
2012
Page(s) :
1-97
Langue(s) :
Anglais
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Thésaurus mots-clés
OPIOIDES
;
HEROINE
;
OPIACES
;
MORPHINE
;
MEDICAMENTS
;
MERE
;
TRAITEMENT
;
NOUVEAU-NE
;
BUPRENORPHINE
;
METHADONE
;
ETUDE RANDOMISEE
;
GROSSESSE
;
FOETUS
;
SYNDROME DE SEVRAGE
Résumé :
CONTENTS:
• Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses. Bandstra E.S., p. 1-4.
• Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Jones H.E., Heil S.H., Baewert A., Arria A.M., Kaltenbach K., Martin P.R., et al., p. 5-27.
• Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Jones H.E., Fischer G., Heil S.H., Kaltenbach K., Martin P.R., Coyle M.G., et al., p. 28-35.
• Fetal assessment before and after dosing with buprenorphine or methadone. Salisbury A.L., Coyle M.G., O'Grady K.E., Heil S.H., Martin P.R., Stine S.M., et al., p. 36-44.
• Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Kaltenbach K., Holbrook A.M., Coyle M.G., Heil S.H., Salisbury A.L., Stine S.M., et al., p. 45-52.
• Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., et al., p. 53-62.
• Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Coyle M.G., Salisbury A.L., Lester B.M., Jones H.E., Lin H., Graf-Rohrmeister K., et al., p. 63-73.
• Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Benningfield M.M., Dietrich M.S., Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., et al., p. 74-82.
• Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Holbrook A.M., Baxter J.K., Jones H.E., Heil S.H., Coyle M.G., Martin P.R., et al., p. 83-90.
• Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. McNicholas L.F., Holbrook A.M., O'Grady K.E., Jones H.E., Coyle M.G., Martin P.R., et al., p. 91-97.
• Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses. Bandstra E.S., p. 1-4.
• Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Jones H.E., Heil S.H., Baewert A., Arria A.M., Kaltenbach K., Martin P.R., et al., p. 5-27.
• Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Jones H.E., Fischer G., Heil S.H., Kaltenbach K., Martin P.R., Coyle M.G., et al., p. 28-35.
• Fetal assessment before and after dosing with buprenorphine or methadone. Salisbury A.L., Coyle M.G., O'Grady K.E., Heil S.H., Martin P.R., Stine S.M., et al., p. 36-44.
• Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Kaltenbach K., Holbrook A.M., Coyle M.G., Heil S.H., Salisbury A.L., Stine S.M., et al., p. 45-52.
• Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., et al., p. 53-62.
• Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Coyle M.G., Salisbury A.L., Lester B.M., Jones H.E., Lin H., Graf-Rohrmeister K., et al., p. 63-73.
• Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Benningfield M.M., Dietrich M.S., Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., et al., p. 74-82.
• Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Holbrook A.M., Baxter J.K., Jones H.E., Heil S.H., Coyle M.G., Martin P.R., et al., p. 83-90.
• Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. McNicholas L.F., Holbrook A.M., O'Grady K.E., Jones H.E., Coyle M.G., Martin P.R., et al., p. 91-97.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection
H. E. JONES ;
S. H. HEIL ;
A. BAEWERT ;
A. M. ARRIA ;
K. KALTENBACH ;
P. R. MARTIN ;
M. G. COYLE ;
P. SELBY ;
G. FISCHER
|
2012
Dans Addiction (Vol.107, Suppl.1, November 2012) Article : Périodique
Dans Addiction (Vol.107, Suppl.1, November 2012) Article : Périodique
Aims: This paper reviews the published literature regarding outcomes following maternal treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects, effects on breast milk and longer-term developmental effects.[...]